tirzepatide phase 3 trial 80 weeks weight change for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN Lilly's retatrutide shows 28% weight

LLY, NVO Stocks Led Mays GLP-1 Rally But This Smaller Differentiated Player Got A Bold 160% Upside Call Truist assumed coverage on VKTX with a 'Buy' rating and an $83 price target, implying an upside of 162% from current levels

For years, the conversation was How much weight can we reduce? Now the more important question may be What are we preserving while reducing weight? If substantial weight loss comes at the cost of excessive lean mass loss, frailty, reduced functional capacity, or nutritional compromise, then the scale alone becomes an incomplete measure of success

Neurotransmitter imbalances were observed, characterized by increased AChE and serotonin levels and decreased dopamine

Plos One 12(7):e0181370